Cognitive and Memory Enhancer Drugs Market by Product and Application - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4580516
  • Report
  • Region: Global
  • 185 pages
  • Allied Analytics LLP
1 of 4
Cognitive enhancers are drugs and supplements, which are majorly used by patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. In addition, these drugs are used by health individuals to improve cognitive functions such as memory, intelligence, motivation, stamina, alertness attention, and concentration.

The global cognitive and memory enhancer drugs market was valued at $3,680 million in 2016, and is projected to reach $6,598 million by 2023, growing at a CAGR of 8.6% from 2017 to 2023. The growth of the global cognitive and memory enhancer drugs market is driven by surge in geriatric population and rise in prevalence of neurological & memory-related disorders. Furthermore, the benefits offered by cognitive drugs such as improved memory and reasoning fuel the market growth. However, ethical issues related to the use of these drugs impede the market growth.

The global cognitive and memory enhancer drugs market is segmented on the basis of product, application, and region. Based on product, the market is categorized into Aricept, Razadyne, Namenda, Exelon, Provigil, Ritalin, Adderall, and others. The applications covered in the study include disease treatment, academic performance, athletic performance, and others. Disease treatment segment is further bifurcated into developmental conditions and neurodegenerative disease. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging trends and dynamics in the global cognitive and memory enhancer drugs market.
This study provides the competitive landscape of the global market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region-and country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Product

Aricept
Exelon
Namenda
Razadyne
Provigil
Ritalin
Adderall
Others

By Application

Disease Treatment
Developmental Conditions
Neurodegenerative Conditions
Academic Performance
Athletic Performance
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

The key players profiled in this report are as follows:

Pfizer Inc.
Eisai Co., Ltd.
Allergan, Inc.
Novartis AG
Shire
Johnson & Johnson
Takeda Pharmaceutical Company Limited
AlternaScript LLC
Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.)
Ceretropic
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top winning strategies
3.2.1.1. Top winning strategies, by year, 2015-2018*
3.2.1.2. Top winning strategies, by development, 2015-2018* (%)
3.2.1.3. Top winning strategies, by company, 2015-2018*
3.2.2. Top investment pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rapidly aging population
3.4.1.2. High incidence of neurodegenerative disorders
3.4.1.3. Benefits of smart drugs
3.4.2. Restraints
3.4.2.1. Ethical issues
3.4.3. Opportunities
3.4.3.1. Effective strength of the drugs

CHAPTER 4: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Aricept
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Exelon
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Namenda
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Razadyne
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Provigil
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Ritalin
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Adderall
4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Others
4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

CHAPTER 5: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Disease treatment
5.2.1. Market size and forecast by type
5.2.2. Developmental conditions
5.2.2.1. Market size and forecast
5.2.3. Neurodegenerative disorders
5.2.3.1. Market size and forecast
5.2.4. Market size and forecast, by region
5.2.5. Market analysis, by country
5.3. Academic performance
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Athletic performance
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

CHAPTER 6: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S. cognitive and memory enhancer drugs market
6.2.2.1.1. U.S. market size and forecast, by product
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada cognitive and memory enhancer drugs market
6.2.2.2.1. Canada market size and forecast, by product
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico cognitive and memory enhancer drugs market
6.2.2.3.1. Mexico market size and forecast, by product
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany cognitive and memory enhancer drugs market
6.3.2.1.1. Germany market size and forecast, by product
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France cognitive and memory enhancer drugs market
6.3.2.2.1. France market size and forecast, by product
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK cognitive and memory enhancer drugs market
6.3.2.3.1. UK market size and forecast, by product
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy cognitive and memory enhancer drugs market
6.3.2.4.1. Italy market size and forecast, by product
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain cognitive and memory enhancer drugs market
6.3.2.5.1. Spain market size and forecast, by product
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe cognitive and memory enhancer drugs market
6.3.2.6.1. Rest of Europe market size and forecast, by product
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by product
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan cognitive and memory enhancer drugs market
6.4.2.1.1. Japan market size and forecast, by product
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China cognitive and memory enhancer drugs market
6.4.2.2.1. China market size and forecast, by product
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India cognitive and memory enhancer drugs market
6.4.2.3.1. India market size and forecast, by product
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Australia cognitive and memory enhancer drugs market
6.4.2.4.1. Australia market size and forecast, by product
6.4.2.4.2. Australia market size and forecast, by application
6.4.2.5. Rest of Asia-Pacific cognitive and memory enhancer drugs market
6.4.2.5.1. Rest of Asia-Pacific market size and forecast, by product
6.4.2.5.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast by country
6.5.2.1. Brazil cognitive and memory enhancer drugs market
6.5.2.1.1. Brazil market size and forecast, by product
6.5.2.1.2. Brazil market size and forecast, by application
6.5.2.2. Saudi Arabia cognitive and memory enhancer drugs market
6.5.2.2.1. Saudi Arabia market size and forecast, by product
6.5.2.2.2. Saudi Arabia market size and forecast, by application
6.5.2.3. South Africa cognitive and memory enhancer drugs market
6.5.2.3.1. South Africa market size and forecast, by product
6.5.2.3.2. South Africa market size and forecast, by application
6.5.2.4. Rest of LAMEA cognitive and memory enhancer drugs market
6.5.2.4.1. Rest of LAMEA market size and forecast, by product
6.5.2.4.2. Rest of LAMEA market size and forecast, by application
6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AlternaScript LLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. Ceretropic
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.4. Eisai Co. Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Johnson & Johnson
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Novartis International AG
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Shire Plc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, "Cognitive and Memory Enhancer Drugs Market by Product and Application: Global Opportunity Analysis and Industry Forecast, 2017-2023" the global cognitive and memory enhancer drugs market was valued at $3,680 million in 2016, and is projected to reach $6,598 million by 2023, growing at a CAGR of 8.6% from 2017 to 2023. Namenda held more than one-fourth share of the total market in 2016.

Cognitive and memory enhancers are the drugs or supplements, which help to improve the cognitive functions such as memory, creativity, and others in patients suffering from diseases such as neurological disorders as well as in healthy individuals. The major factors that contribute to the market growth include growth in geriatric population prone to neurological disorders such as Alzheimer. Moreover, rise in adoption of cognitive drugs owing to its benefits such as improved physical and mental performance boosts the market growth. However, the ethical issues related with the use of such drugs restrain the growth of this market.

Namenda generated the maximum revenue in the global cognitive and memory enhancer drugs market in 2016, and is expected to dominate the market till 2023. Exelon segment is expected to register the highest CAGR of 10.9% during the forecast period, owing to increase in awareness among people towards improved physical performance.

Disease treatment application segment is expected to dominate the market in the future, owing to increase in the number of patients suffering from neurological diseases such as Alzheimer's. On the other hand, academic performance segment is estimated to exhibit a CAGR of 10.2% during the forecast period

Key findings of the Cognitive And Memory Enhancer Drugs Market:

Razadyne contributed for more than one-sixth share of the global cognitive and memory enhancer drugs market in 2016.
Provigil is projected to grow at a significant CAGR of 10.4% during the analysis period.
Athletic performance is expected to grow at a significant CAGR of 9.8% from 2017 to 2023.
Germany and France were the major shareholders in 2016, together accounting for more than one-third share of the European cognitive and memory enhancer drugs market.
Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific market.

The Asia-Pacific market is projected to grow at the highest CAGR of 9.6% during the forecast period, owing to improvement in healthcare infrastructure and rise in expenditures in the emerging markets (such as India and China) to cater to the unmet medical needs.

The major companies profiled in the report are Pfizer Inc., Eisai Co., Ltd., Allergan, Inc., Novartis AG, Shire, Johnson & Johnson, Takeda Pharmaceutical Company Limited, AlternaScript LLC, Cephalon, Inc. (Teva Pharmaceutical Industries Ltd.), and Ceretropic.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll